Market Cap (In USD)
335.19 Million
Revenue (In USD)
-
Net Income (In USD)
-96.65 Million
Avg. Volume
659.79 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.625-16.775
- PE
- -
- EPS
- -
- Beta Value
- 2.034
- ISIN
- US68062P1066
- CUSIP
- 68062P106
- CIK
- 1750284
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Sean P. Bohen M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.olema.com
- Ipo Date
- 2020-11-19
- Details
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
More Stocks
-
GCTKGlucoTrack, Inc.
GCTK
-
VIPCLOTHNGVIP Clothing Limited
VIPCLOTHNG
-
ZUARIINDZuari Industries Limited
ZUARIIND
-
CDIOW
-
RNT
-
SCHAEFFLERSchaeffler India Limited
SCHAEFFLER
-
PRIVISCLPrivi Speciality Chemicals Limited
PRIVISCL
-
IIQINOVIQ Ltd
IIQ